SVA:CC - Sernova Receives Conditional Approval to Up-list to the Toronto Stock Exchange
(TheNewswire)
London, Ontario – TheNewswire - May 24 , 2022 – Sernova Corp.(TSXV:SVA; ) ( OTC:SEOVF ) ; ( FSE: PSH); ( XETRA:PSH), a clinical-stage company and leader in regenerative medicinecell therapeutics , ispleased to announce that it has received conditional approval to listits common shares on the Toronto Stock Exchange (the "TSX")and move off of the TSX Venture Exchange ("TSXV").
Final approval of the listing is subject to the Companymeeting certain customary conditions required by the TSX. The companywill issue a press release once the TSX confirms the date when tradingof Sernova’s common shares is expected to commence on the TSX. Uponcompletion of the final listing requirements, Sernova’s commonshares will be delisted from the TSXV.
Dr. Philip Toleikis, President and CEO of Sernova Corpcommented, “Moving onto the Toronto Stock Exchange represents amilestone achievement in our evolution as an emerging regenerativemedicine company. Up-listing will provide enhanced liquidity andbring new visibility and investors into the company as we advance ourtherapeutic cell therapy platform with the goal to provide‘functional cures’ for multiple diseases including type onediabetes, hemophilia and thyroid disease.”
Shareholders are not required to exchange their sharecertificates or take any other action in connection with the TSXlisting, as there will be no change in the trading symbol or CUSIP forthe common shares. The Company will continue to trade its commonshares on the OTCQB market in the United States under the symbol"SEOVF", and the Frankfurt exchange under the symbol"PSH".
ABOUT SERNOVA CORP. AND THE CELLPOUCH SYSTEM ™ PLATFORM FOR CELL THERAPY
Sernova Corp. is developing regenerative medicinetherapeutic technologies using a medical device and immune protectedtherapeutic cells (i.e., human donor cells, corrected human cells andstem-cell derived cells) to improve the treatment and quality of lifeof people with chronic metabolic diseases such as insulin-dependentdiabetes, blood disorders including hemophilia, and other diseasestreated through replacement of proteins or hormones missing or inshort supply within the body.
The Cell Pouch ™ isa proprietary, scalable, implantable macro- encapsulation devicesolution designed for the long-term survival and function oftherapeutic cells. After implantation, the device incorporates withtissue, forming highly vascularized, native tissue chambers for thetransplantation and function of therapeutic cells, that releaseproteins and hormones as required to treat disease.
The Cell Pouch along with therapeutic cells, has been shown to providelong-term safety and efficacy in small and large animal models ofdiabetes and has been proven to provide a biologically compatibleenvironment for insulin-producing cells in humans in a Canadianfirst-in-human study. Sernova is currently conducting a Phase 1/2clinical trial study at the University of Chicago. Encouraging interimresults have been presented at several international scientificconferences.
For more information, please visit www.sernova.com
For further information contact:
Sernova Corp.
Christopher Barnes
Tel: (519) 858-5126
christopher.barnes@sernova.com
Investors:
Corey Davis, Ph.D.
LifeSci Advisors, LLC
Tel: 212-915-2577
Media:
Elizabeth Miller, MD
LifeSci Communications
Neither the TSXV nor the TSX acceptsresponsibility for the adequacy or accuracy of this newsrelease.
FORWARD-LOOKING INFORMATION
This release may contain forward-looking statements.Forward-looking statements are statements that are not historicalfacts and are generally, but not always, identified by the words“expects”, “plans”, “anticipates”, “believes”,“intends”, “estimates”, “projects”, “potential” andsimilar expressions, or that events or conditions “will”,“would”, “may”, “could” or “should” occur. AlthoughSernova believes the expectations expressed in such forward-lookingstatements are based on reasonable assumptions, such statements arenot guarantees of future performance, and actual results may differmaterially from those in forward-looking statements. Forward-lookingstatements are based on the beliefs, estimates, and opinions ofSernova’s management on the date such statements were made, whichinclude our beliefs about the conduct and outcome of clinical trials,and the development of new technologies, cell therapy solutions and orproducts. The information disclosed represents results from onepatient and may not be representative of all study patients or of thefinal study results. Sernova expressly disclaims any intention orobligation to update or revise any forward-looking statements whetheras a result of new information, future events or otherwise.
Copyright (c) 2022 TheNewswire - All rights reserved.